Cargando…

PB1894: MIR-199A EXPRESSION PROFILES IN CHRONIC MYELOID LEUKEMIA: A PRELIMINARY STUDY

Detalles Bibliográficos
Autores principales:	Frikha, R., Belguith, I., Leila, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431641/ http://dx.doi.org/10.1097/01.HS9.0000850428.68753.a6

Ejemplares similares

PB1894: NPM1 MUTATED ACUTE MYELOID LEUKEMIA: THE CO-MUTATION PATTERNS MAY BE ASSOCIATED WITH PROGNOSIS
por: Varelas, Christos, et al.
Publicado: (2023)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

PB1843: ACUTE MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME: EXPERIENCE OF SFAX HEMATOLOGY DEPARTMENT
por: Siala, N., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1812: CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA IN PEDIATRIC POPULATION: THE RESULTS OF A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT
por: Musteata, V.
Publicado: (2022)

PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
por: Qi, Feiyang, et al.
Publicado: (2023)

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

PB2249: ATYPICAL CHRONIC MYELOID LEUKEMIA (ACML) AND AUTOIMMUNE DISEASE: REPORT OF TWO CASES.
por: Tatarelli, Caterina, et al.
Publicado: (2023)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
por: Hassan, Hammad, et al.
Publicado: (2023)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

PB1876: SIXTEEN YEARS OF EXPERIENCE WITH THE MRC-10 PROTOCOL FOR THE TREATMENT OF ADULT ACUTE MYELOID LEUKEMIA IN THE SOUTH OF TUNISIA
por: Siala, Nour, et al.
Publicado: (2023)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
por: Mo, Qianxing, et al.
Publicado: (2023)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
por: Ajtić, Olivera Mitrović, et al.
Publicado: (2023)

PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)
por: Piras, Giovanna, et al.
Publicado: (2023)

PB1965: INSIGHTS INTO RELAPSED AND REFRACTORY CHRONIC MYELOID LEUKEMIA: MOLECULAR-GENETIC, BIOCHEMICAL AND PROGNOSIS PATTERNS
por: Musteata, Vasile
Publicado: (2023)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN.
por: Haidary, A. M., et al.
Publicado: (2022)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
por: Urbano, M., et al.
Publicado: (2022)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
por: Pantic, N., et al.
Publicado: (2022)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
por: Gordienko, Alla, et al.
Publicado: (2023)

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
por: Huang, Nanfang, et al.
Publicado: (2023)

PB1794: EFFECT OF HYPOXIA ON CD47 EXPRESSION IN HUMAN ACUTE MYELOID LEUKEMIA CELL LINES
por: Wang, C., et al.
Publicado: (2022)

PB1982: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF CHRONIC MYELOID LEUKEMIA: EXPERIENCE OF FATTOUMA BOURGUIBA HOSPITAL OF MONASTIR
por: Lakhel, Sana, et al.
Publicado: (2023)

PB1795: BIO-INSPIRED NANOMEDICINE FOR TARGETED ACUTE MYELOID LEUKEMIA IMMUNOTHERAPY
por: Wang, X., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Mahtat, E. M., et al.
Publicado: (2022)

PB1834: ACQUIRED FACTOR VII DEFICIENCY ASSOCIATED WITH ACUTE MYELOID LEUKEMIA
por: Hafsa, Haifa, et al.
Publicado: (2023)

PB1837: ANTIBIOTICS; A POSSIBLE ALTERNATE TREATMENT OPTION FOR MYELOID LEUKEMIA
por: Maham, Syeda, et al.
Publicado: (2023)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

PB1891: EARLY DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: Koubaa, Asma, et al.
Publicado: (2023)

PB1819: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: kasser, O., et al.
Publicado: (2022)

PB1893: THE STUDY OF SET GENE AND PROTEIN PHOSPHATASE 2A IN CHRONIC MYELOID LEUKEMIA AND THEIR ROLE IN DISEASE PROGRESSION
por: Fathy, H., et al.
Publicado: (2022)

PB1823: SECONDARY ACUTE MYELOID LEUKEMIA AND DE NOVO ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES DISTINCT LANDSCAPE, OR THE SAME DISEASE?
por: Jagurinoski, M., et al.
Publicado: (2022)

PB1907: EPIDEMIOLOGICAL PROFILE AND DIAGNOSTIC FEATURES OF ACUTE MYELOBLASTIC LEUKEMIA IN ADULTS: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Siala, Nour, et al.
Publicado: (2023)

PB1920: CLINICOHEMATOLIGICAL CHARACTERISTICS AND CYTOGENETIC PROFILE OF CHRONIC MYELOMONOCYTIC LEUKEMIA; AN EXPERIENCE FROM PAKISTAN
por: ANWAR, N., et al.
Publicado: (2022)

PB1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS
por: Abdennebi, Naima, et al.
Publicado: (2023)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8bkp1t2jr9jpg6s3ls8o0dqq83